Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
Eligible participants will be assigned to one of five experimental arms. In Experimental Arm 1, participants will receive MBG453 alone, every 4 weeks, to confirm safety and tolerability of RD. In Experimental Arm 2, participants will receive NIS793 alone, every 3 weeks, to establish RD in this indication and confirm safety and tolerability. In Experimental Arm 3, participants will receive canakinumab alone, every 4 weeks, to confirm safety and tolerability of RD. In Experimental Arm 4, participants will receive MBG453 + NIS793 combined treatment every 3 weeks to confirm safety and tolerability of combination RD. In Experimental Arm 5 MBG453 + canakinumab combined treatment every 4 weeks to confirm safety and tolerability of combination RD.